AIM ImmunoTech Inc. (AIM) Form 8-K — Sep 4, 2026
AIM ImmunoTech entered into five exchange agreements with Streeterville Capital, LLC between August 31 and September 3, 2026, converting approximately $1,224,341 of its February 2024 promissory note into 5,065,840 shares of common stock at an average conversion price of approximately $0.24 per share. As of September 3, 2026 the promissory note is satisfied in full and no amounts remain owing, removing what was originally a $3,301,250 obligation without a cash outlay. Stockholders had pre-approved the conversion at the July 15, 2026 special meeting under NYSE American Company Guide Sections 713(a) and 713(b).
Key figures
- Debt Amount
- 1224341
- Offering Price
- 0.24
- Shares Offered
- 5065840
- Note origination date
- February 16, 2024
- Registration exemption
- Section 3(a)(9) exchange with existing security holder
- Exchange agreements count
- 5
- Stockholder approval date
- 2026-07-15
- Shares issued free trading
- Yes
- Original note principal usd
- 3301250
Price after filing
Close on the filing date to close N calendar days later (from $0.23). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.